Beyond histology: Lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection

Transplantation

Volumn 89, Issue 8, 2010, Pages 962-967

  Everly, Matthew J ^a   Rebellato, Lorita M ^b   Ozawa, Mikki ^c   Briley, Kimberly P ^b   Catrou, Paul G ^b   Haisch, Carl E ^b   Terasaki, Paul I ^a  

^a TERASAKI FOUNDATION LABORATORY   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

^c One Lambda Inc   (United States)

Author keywords

Allograft survival; Antibodies; Antibody mediated rejection; Human leukocyte antigen

Indexed keywords

CORTICOSTEROID; HLA ANTIBODY; OKT 3; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY MEDIATED REJECTION; ANTIBODY PRODUCTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE; GRAFT RECIPIENT; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; MALE; PLASMAPHERESIS; PRIORITY JOURNAL;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; BIOPSY; DOWN-REGULATION; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KAPLAN-MEIERS ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MUROMONAB-CD3; PLASMAPHERESIS; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 77951294085     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181cbac02     Document Type: Article

References (25)

1. Terasaki PI, Cai J. Human leukocyte antigen antibodies and chronic rejection: From association tocausation.Transplantation2008; 86: 377.
2. Smith RN, Kawai T, Boskovic S, et al. Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys. Am J Transplant 2008; 8: 1662.
3. Cai J, Terasaki PI. Humoral theory of transplantation: Mechanism, prevention, and treatment. Hum Immunol 2005; 66: 334.
4. Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003; 3: 665.
5. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033.
6. Higgins R, Hathaway M, Lowe D, et al. Blood levels of donor-specific human leukocyte antigen antibodies after renal transplantation: Resolution of rejection in the presence of circulating donor-specific antibody. Transplantation 2007; 84: 876.
7. Tang AH, Platt JL. Accommodation of grafts: Implications for health and disease. Hum Immunol 2007; 68: 645.
8. Zarkhin V, Li L, Kambham N, et al. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant 2008; 8: 2607.
9. Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063.
10. Ozawa M, Rebellato LM, Terasaki PI, et al. Longitudinal testing of 266 renal allograft patients for HLA and MICA antibodies: Greenville experience. Clin Transpl 2006: 265.
11. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria\An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708.
12. Solez K, Colvin RB, Racusen LC, et al. Banff'05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518
13. Fifteen years of HLA: What is the importance of HLA compatibility for clinical outcome of renal transplantations? Vox Sang 1978; 34: 171.
14. Kaneku HK, Terasaki PI. Thirty year trend in kidney transplants: UCLA and UNOS Renal Transplant Registry. Clin Transpl 2006: 1.
15. Ozawa M, Terasaki PI, Lee JH, et al. 14th International HLA and Im-munogenetics Workshop: Report on the Prospective Chronic Rejection Project. Tissue Antigens 2007; 69(suppl 1): 174.
16. Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1.
17. Mizutani K, Terasaki P, Hamdani E, et al. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 2007; 7: 1027.
18. Locke JE, Zachary AA, Warren DS, et al. Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. Am J Transplant 2009; 9: 2136.
19. Halloran PF, Schlaut J, Solez K, et al. The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 1992; 53: 550.
20. Halloran PF, Wadgymar A, Ritchie S, et al. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation 1990; 49: 85.
21. Feucht HE, Felber E, Gokel MJ, et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991; 86:464.
22. Worthington JE, Martin S, Al-Husseini DM, et al. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003; 75: 1034.
23. Lee PC, Zhu L, Terasaki PI, et al. HLA-specific antibodies developed in the first year post transplant are predictive of chronic rejection and renal graft loss. Transplantation 2009; 88: 568.
24. Jindra PT, Zhang X, Mulder A, et al. Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. Transplantation 2006; 82(1 suppl): S33.
25. Zhang X, Reed EF. Effect of antibodies on endothelium. Am J Transplant 2009; 9: 2459.